<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006685.pub4" GROUP_ID="EPILEPSY" ID="863606021412100298" MERGED_FROM="" MODIFIED="2016-05-03 12:05:21 +0100" MODIFIED_BY="Rachael Kelly" REVIEW_NO="001" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="7.2">
<COVER_SHEET MODIFIED="2016-05-03 12:05:21 +0100" MODIFIED_BY="Rachael Kelly">
<TITLE MODIFIED="2013-06-19 14:01:40 +0100" MODIFIED_BY="[Empty name]">Pharmacological treatment for Kleine-Levin syndrome</TITLE>
<CONTACT MODIFIED="2016-05-03 12:05:21 +0100" MODIFIED_BY="Rachael Kelly"><PERSON ID="AFBB514F82E26AA20100271A20CF4B41" ROLE="AUTHOR"><PREFIX>Mr</PREFIX><FIRST_NAME>Marcio</FIRST_NAME><MIDDLE_INITIALS>M</MIDDLE_INITIALS><LAST_NAME>de Oliveira</LAST_NAME><POSITION>Physician</POSITION><EMAIL_1>docmmo@uol.com.br</EMAIL_1><ADDRESS><ORGANISATION>Universidade Federal de São Paulo</ORGANISATION><ADDRESS_1>Rua Pedro de Toledo, 598</ADDRESS_1><CITY>São Paulo</CITY><ZIP>04039-001</ZIP><REGION>São Paulo</REGION><COUNTRY CODE="BR">Brazil</COUNTRY><PHONE_1>+55 11 55752970</PHONE_1><FAX_1>+55 11 55752970</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2016-05-03 12:05:21 +0100" MODIFIED_BY="Rachael Kelly"><PERSON ID="AFBB514F82E26AA20100271A20CF4B41" ROLE="AUTHOR"><PREFIX>Mr</PREFIX><FIRST_NAME>Marcio</FIRST_NAME><MIDDLE_INITIALS>M</MIDDLE_INITIALS><LAST_NAME>de Oliveira</LAST_NAME><POSITION>Physician</POSITION><EMAIL_1>docmmo@uol.com.br</EMAIL_1><ADDRESS><ORGANISATION>Universidade Federal de São Paulo</ORGANISATION><ADDRESS_1>Rua Pedro de Toledo, 598</ADDRESS_1><CITY>São Paulo</CITY><ZIP>04039-001</ZIP><REGION>São Paulo</REGION><COUNTRY CODE="BR">Brazil</COUNTRY><PHONE_1>+55 11 55752970</PHONE_1><FAX_1>+55 11 55752970</FAX_1></ADDRESS></PERSON><PERSON ID="73EBB10682E26AA201E0E19D9634A52F" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Cristiane</FIRST_NAME><LAST_NAME>Conti</LAST_NAME><POSITION>Clinical Neurologist, PhD student</POSITION><EMAIL_1>contic@terra.com.br</EMAIL_1><ADDRESS><ORGANISATION>Universidade Federal de São Paulo</ORGANISATION><CITY>São Paulo</CITY><ZIP>04039-001</ZIP><REGION>São Paulo</REGION><COUNTRY CODE="BR">Brazil</COUNTRY><PHONE_1>+55 11 55752970</PHONE_1><FAX_1>+55 11 55752970</FAX_1></ADDRESS></PERSON><PERSON ID="38D0FA0C82E26AA201BA4B547DC85853" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Gilmar</FIRST_NAME><MIDDLE_INITIALS>F</MIDDLE_INITIALS><LAST_NAME>Prado</LAST_NAME><POSITION>Professor</POSITION><EMAIL_1>gilmarunifesp@yahoo.com.br</EMAIL_1><ADDRESS><DEPARTMENT>Department of Neurology</DEPARTMENT><ORGANISATION>Escola Paulista de Medicina, Universidade Federal de São Paulo</ORGANISATION><CITY>São Paulo</CITY><REGION>São Paulo</REGION><COUNTRY CODE="BR">Brazil</COUNTRY><PHONE_1>+55 11 5081 6629</PHONE_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2016-05-03 12:02:34 +0100" MODIFIED_BY="Rachael Kelly">
<UP_TO_DATE>
<DATE DAY="7" MONTH="4" YEAR="2016"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="7" MONTH="4" YEAR="2016"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="7" MONTH="4" YEAR="2018"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2007"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2009"/>
<LAST_CITATION_ISSUE ISSUE="5" YEAR="2016"/>
</DATES>
<WHATS_NEW MODIFIED="2016-04-07 13:48:09 +0100" MODIFIED_BY="Márcio M. de Oliveira">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2016-04-07 13:48:09 +0100" MODIFIED_BY="Márcio M. de Oliveira">
<DATE DAY="7" MONTH="4" YEAR="2016"/>
<DESCRIPTION>
<P>Searches updated 7 April 2016.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2016-04-07 12:59:56 +0100" MODIFIED_BY="Márcio M. de Oliveira">
<DATE DAY="7" MONTH="4" YEAR="2016"/>
<DESCRIPTION>
<P>No new studies identified; conclusions are unchanged.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2015-07-10 13:42:42 +0100" MODIFIED_BY="Graham Chan">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2015-07-10 13:42:42 +0100" MODIFIED_BY="Graham Chan">
<DATE DAY="7" MONTH="5" YEAR="2013"/>
<DESCRIPTION>
<P>Conclusions unchanged.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2015-07-10 13:42:37 +0100" MODIFIED_BY="Graham Chan">
<DATE DAY="2" MONTH="5" YEAR="2013"/>
<DESCRIPTION>
<P>Searches updated; no new studies identified.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2013-05-02 16:56:43 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="13" MONTH="3" YEAR="2012"/>
<DESCRIPTION>
<P>Searches updated 24 October 2011; no new studies identified.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2012-03-14 14:42:06 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="5" MONTH="3" YEAR="2010"/>
<DESCRIPTION>
<P>Searches updated 5 March 2010; no new trials identified.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-07-27 14:09:42 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="19" MONTH="8" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2016-03-23 14:01:20 +0000" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES MODIFIED="2016-03-23 14:01:20 +0000" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2016-03-23 14:01:20 +0000" MODIFIED_BY="[Empty name]">
<NAME>National Institute for Health Research (NIHR), UK</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION>
<P>This review was supported by the National Institute for Health Research, via Cochrane Infrastructure funding to the Epilepsy Group. The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the Systematic Reviews Programme, NIHR, NHS or the Department of Health.</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2016-04-25 14:49:08 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2016-04-07 15:13:32 +0100" MODIFIED_BY="Márcio M. de Oliveira">
<TITLE MODIFIED="2013-06-19 14:03:49 +0100" MODIFIED_BY="[Empty name]">Pharmacological treatment for Kleine-Levin syndrome</TITLE>
<SUMMARY_BODY MODIFIED="2016-04-07 15:13:32 +0100" MODIFIED_BY="Márcio M. de Oliveira">
<P>
<B>Background</B>
</P>
<P>Kleine-Levin syndrome (KLS) is a rare disorder that mainly affects adolescent men. It is characterised by recurrent episodes of hypersomnia (excessive sleepiness), hyperphagia (overeating), and abnormal behaviour. The frequency and nature of the attacks can disrupt the individual's social, professional, and family life. The cause of KLS is not known. Several treatments have been used, including stimulant, anti-epileptic, anti-depressant, and anti-psychotic drugs, with some benefit reported, but because of the rarity of the condition, long-term follow-up of participants is difficult.</P>
<P>
<B>Objectives</B>
</P>
<P>The authors of this review aimed to identify and evaluate randomised controlled trials (RCTs) studying the effectiveness of pharmacological treatment for Kleine-Levin syndrome.</P>
<P>
<B>Results</B>
</P>
<P>We were not able to find any RCTs. Good-quality evidence is therefore lacking, and therapeutic trials with a double-blind, placebo-controlled design are needed.</P>
<P>The evidence was current to 7 April 2016.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2016-04-25 14:46:29 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2016-04-25 14:46:29 +0100" MODIFIED_BY="[Empty name]">
<P>This is an updated version of the original Cochrane review, published in 2009, Issue 2.</P>
<P>Kleine-Levin syndrome (KLS) is a rare disorder that mainly affects adolescent men. It is characterised by recurrent episodes of hypersomnia, usually accompanied by hyperphagia, cognitive and mood disturbances, abnormal behaviour, such as hypersexuality, and signs of dysautonomia.</P>
<P>In 1990, the diagnostic criteria for Kleine-Levin syndrome were modified in the International Classification of Sleep Disorders, where KLS was defined as a syndrome comprised of recurring episodes of undue sleepiness lasting some days, which may or may not be associated with hyperphagia and abnormal behaviour. According to the International Classification of Sleepiness Disorders, 3rd version (ICSD-3), revised in 2014, the Kleine-Levin syndrome is a disorder characterized by recurrent episodes of hypersomnia that last from two days to four weeks, with at least annual recurrence, and hyperphagia (rapid consumption of a large amount of food), usually with onset in early adolescence in males but occasionally in later life and in women. A monosymptomatic form of the disorder with hypersomnia only can occur without binge eating or hypersexuality.</P>
<P>The cause of Kleine-Levin syndrome remains unknown, and several treatment strategies have been used. Some medications have been reported to provide benefit in the treatment of patients with KLS, but because of the rarity of the condition, no long-term follow-up therapies have yet been described.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2016-04-06 10:09:17 +0100" MODIFIED_BY="[Empty name]">
<P>This review aimed to evaluate:</P>
<P>1. whether pharmacological treatment for Kleine Levin syndrome was effective and safe.<BR/>2. which drug or category of drugs was effective and safe.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2016-04-07 15:13:13 +0100" MODIFIED_BY="Márcio M. de Oliveira">
<P>For the latest update, we searched the following sources: the Cochrane Epilepsy Group Specialized Register (7 April 2016); the Cochrane Central Register of Controlled Trials (CENTRAL) via the Cochrane Register of Studies Online CRSO (7 April 2016); MEDLINE (1946 to April 2016); LILACS (7 April 2016); <A HREF="https://clinicaltrials.gov/">ClinicalTrials.gov</A> (7 April 2016); <A HREF="http://apps.who.int/trialsearch/">WHO International Clinical Trials Registry Platform ICTRP</A> (7 April 2016); reference lists of sleep medicine textbooks; review articles and reference lists of articles identified by the search strategies.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2016-04-06 10:09:18 +0100" MODIFIED_BY="[Empty name]">
<P>All randomised controlled trials (RCTs) and quasi-randomised controlled trials looking at pharmacological interventions for Kleine-Levin syndrome were eligible. We had planned to include both parallel-group and cross-over studies.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2016-04-06 10:09:19 +0100" MODIFIED_BY="[Empty name]">
<P>Two review authors (MMO and CC) had planned to extract the data reported in the original articles.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>No studies met the inclusion criteria for this systematic review.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2013-06-19 14:03:48 +0100" MODIFIED_BY="[Empty name]">
<P>Therapeutic trials of pharmacological treatment for Kleine-Levin syndrome with a double-blind, placebo-controlled design are needed.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2016-04-25 14:49:08 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2016-04-25 14:49:08 +0100" MODIFIED_BY="[Empty name]">
<P>This review is an update of a previously published review in the <I>Cochrane Database of Systematic Reviews</I> (2009. Issue 2) on 'Pharmacological treatment for Kleine-Levin syndrome' (<LINK REF="REF-Oliveira-2013" TYPE="REFERENCE">Oliveira 2013</LINK>).</P>
<P>Kleine-Levin syndrome (KLS) is a rare disorder with an estimated prevalence of one to five cases per million population (<LINK REF="REF-ISCD_x002d_3-2014" TYPE="REFERENCE">ISCD-3 2014</LINK>) that mainly affects adolescent men. It is characterised by recurrent episodes of hypersomnia, usually accompanied by hyperphagia, cognitive and mood disturbances, abnormal behaviour, such as hypersexuality, and signs of dysautonomia (<LINK REF="REF-ICSD-1990" TYPE="REFERENCE">ICSD 1990</LINK>; <LINK REF="REF-Kleine-1925" TYPE="REFERENCE">Kleine 1925</LINK>; <LINK REF="REF-Levin-1936" TYPE="REFERENCE">Levin 1936</LINK>; <LINK REF="REF-ISCD_x002d_3-2014" TYPE="REFERENCE">ISCD-3 2014</LINK>).</P>
<P>In 1815, Satterley presented the case of a 16-year old male with hypersomnia and hyperphagia following a short period of fever and headache. Kleine-Levin syndrome was first described by Kleine in 1925 (<LINK REF="REF-Kleine-1925" TYPE="REFERENCE">Kleine 1925</LINK>); this description was elaborated on by Levin in 1936 (<LINK REF="REF-Levin-1936" TYPE="REFERENCE">Levin 1936</LINK>), but it was not named Kleine-Levin syndrome until 1942, by Crichtley and Hoffman (<LINK REF="REF-Critchley-1942" TYPE="REFERENCE">Critchley 1942</LINK>). Kleine-Levin syndrome was further defined by Critchley in 1962 (<LINK REF="REF-Critchley-1962" TYPE="REFERENCE">Critchley 1962</LINK>), and by Schmidt in 1990, who established the following diagnostic criteria:<BR/>
</P>
<UL>
<LI>Predominance in adolescent males;</LI>
<LI>Onset in adolescence;</LI>
<LI>Periodic hypersomnia;</LI>
<LI>Hyper/mega/polyphagia;</LI>
<LI>Association with behavioural and psychological changes;</LI>
<LI>Benign clinical course with spontaneous disappearance of clinical symptoms;</LI>
<LI>Lack of other neurological or psychiatric disease.</LI>
</UL>
<P>In 1990, the diagnostic criteria for KLS were modified in the International Classification of Sleep Disorders, where it was defined as a syndrome comprised of recurring episodes of undue sleepiness lasting some days, which may, or may not, be associated with hyperphagia and abnormal behaviour (<LINK REF="REF-ICSD-1990" TYPE="REFERENCE">ICSD 1990</LINK>). According to the International Classification of Sleepiness Disorders, 3rd version (ICSD-3), revised in 2014, Kleine-Levin syndrome is a rare sleep disorder characterized by recurrent episodes of severe hypersomnia associated with cognitive and behavioral disturbances such as confusion, derealization, apathy, compulsive eating, and hypersexuality. Episodes last a few days to several weeks and are separated by weeks or months of normal sleep and behavior. KLS is categorized as a central disorder of hypersomnolence (<LINK REF="REF-ISCD_x002d_3-2014" TYPE="REFERENCE">ISCD-3 2014</LINK>).</P>
<P>The cause of KLS remains unknown, although numerous atypical or incomplete causes have been hypothesised:<BR/>
</P>
<UL>
<LI>Diencephalic-hypothalamic dysfunction, reported with hypothalamic and third ventricle tumours, has similar symptoms, suggesting hypothalamic or circadian dysfunction as a cause (<LINK REF="REF-Fulton-1929" TYPE="REFERENCE">Fulton 1929</LINK>; <LINK REF="REF-Haugh-1983" TYPE="REFERENCE">Haugh 1983</LINK>).</LI>
<LI>Abnormalities in serotonin and dopamine metabolism have been reported, suggesting a neurotransmitter imbalance in the serotonergic or dopaminergic pathway (<LINK REF="REF-Chesson-1991" TYPE="REFERENCE">Chesson 1991</LINK>; <LINK REF="REF-Koerber-1984" TYPE="REFERENCE">Koerber 1984</LINK>).</LI>
<LI>Inflammatory lesions in the thalamus, diencephalon and midbrain have been described in postmortem neuropathological case reports, suggesting a viral infection (<LINK REF="REF-Fenzi-1993" TYPE="REFERENCE">Fenzi 1993</LINK>; <LINK REF="REF-Merriam-1986" TYPE="REFERENCE">Merriam 1986</LINK>; <LINK REF="REF-Salter-1993" TYPE="REFERENCE">Salter 1993</LINK>).</LI>
<LI>Stress status, sleep deprivation, and alcohol abuse have also been suggested as triggers of KLS (<LINK REF="REF-Russel-1992" TYPE="REFERENCE">Russel 1992</LINK>).</LI>
<LI>A genetic basis for the disorder has been suggested by the preponderance of cases in the Ashkenazi Jewish population, suggesting a founder effect, as well as numerous reports of familial cases. To date, however, no specific genes have been identified (<LINK REF="REF-ISCD_x002d_3-2014" TYPE="REFERENCE">ISCD-3 2014</LINK>).</LI>
</UL>
<P>Because of the frequency and the nature of the attacks a person can suffer with KLS, individuals often experience disruption to their social, family, and professional life.</P>
<P>Several treatment strategies have been used:<BR/>
</P>
<UL>
<LI>Stimulant drugs (methylphenidate, modafinil, pemoline-piracetam-meclofenoxate, D-amphetamine, ephedrine, meta-amphetamine, amphetamine, etc.);</LI>
<LI>Anti-epileptic drugs (valproic acid, carbamazepine, amobarbital, phenobarbital, phenytoin, etc.);</LI>
<LI>Anti-depressants (imipramine, monoamine oxidase inhibitors (MAOIs), moclobemide, clomipramine, amineptine, fluoxetine, fluvoxamine, sertraline, methysergide, trazodone, etc.);</LI>
<LI>Anti-psychotic drugs (haloperidol, chlorpromazine, levomepromazine, trifluoperazine, thioridazine, clozapine, risperidone, etc.);</LI>
<LI>Anti-virals (acyclovir);</LI>
<LI>Lithium;</LI>
<LI>Hydrocortisone;</LI>
<LI>Melatonin;</LI>
<LI>Benzodiazepines;</LI>
<LI>Levodopa-benserazide.</LI>
</UL>
<P>These medications have been reported to provide some benefit in the treatment of patients with KLS, but because of the rarity of the condition, no long-term follow-up therapies have yet been described.</P>
</BACKGROUND>
<OBJECTIVES MODIFIED="2016-04-06 10:10:25 +0100" MODIFIED_BY="[Empty name]">
<P>This review aimed to evaluate:</P>
<P>(1) whether pharmacological treatment for Kleine-Levin syndrome was effective and safe;</P>
<P>(2) which drug or category of drugs was effective and safe.</P>
</OBJECTIVES>
<METHODS MODIFIED="2016-04-07 15:15:41 +0100" MODIFIED_BY="Márcio M. de Oliveira">
<SELECTION_CRITERIA MODIFIED="2016-04-06 10:10:57 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2016-04-06 10:10:27 +0100" MODIFIED_BY="[Empty name]">
<P>All randomised controlled trials (RCTs) of pharmacological treatment for Kleine-Levin syndrome. We also had planned to include quasi-randomised controlled trials (using inadequate allocation assignment such as date of birth, day of the week or month of the year, medical record number or alternate allocation). We had planned to include both parallel-group and cross-over studies.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2016-04-06 10:10:49 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Inclusion criteria</HEADING>
<P>We considered children and adults who met the established clinical criteria for KLS (<LINK REF="REF-Critchley-1962" TYPE="REFERENCE">Critchley 1962</LINK>; <LINK REF="REF-ICSD-1990" TYPE="REFERENCE">ICSD 1990</LINK>):</P>
<P>
<LINK REF="REF-ICSD-1990" TYPE="REFERENCE">ICSD 1990</LINK>:</P>
<UL>
<LI>Recurring episodes of undue sleepiness lasting some days;</LI>
<LI>Hyperphagia (not obligatory);</LI>
<LI>Abnormal behaviour (not obligatory).</LI>
</UL>
<P>
<LINK REF="REF-Critchley-1962" TYPE="REFERENCE">Critchley 1962</LINK>:</P>
<UL>
<LI>Predominance in adolescent males; </LI>
<LI>Onset in adolescence;</LI>
<LI>Periodic hypersomnia;</LI>
<LI>Hyper/mega/polyphagia;</LI>
<LI>Associated behavioural and psychological changes;</LI>
<LI>Benign clinical course with spontaneous disappearance of clinical symptoms;</LI>
<LI>Lack of other neurological or psychiatric disease.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Exclusion criteria</HEADING>
<P>We excluded studies that predominantly recruited participants with narcolepsy, obstructive sleep apnoea, schizophrenia, bipolar affective disorder, obsessive-compulsive disorder, frontal brain tumour, third ventricle tumour, drug or alcohol abuse, encephalopathies, bulimia, atypical depressive disease, and delayed sleep maturation.</P>
</SUBSECTION>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2016-04-06 10:10:53 +0100" MODIFIED_BY="[Empty name]">
<P>We included all drugs used for the treatment of KLS.</P>
<SUBSECTION>
<HEADING LEVEL="4">Pharmacological interventions</HEADING>
<UL>
<LI>Stimulant drugs (methylphenidate, modafinil, pemoline-piracetam-meclofenoxate, D-amphetamine, ephedrine, meta-amphetamine, amphetamine, etc.);</LI>
<LI>Anti-epileptic drugs (valproic acid, carbamazepine, amobarbital, phenobarbital, phenytoin, etc.);</LI>
<LI>Anti-depressants (imipramine, MAOIs, moclobemide, clomipramine, amineptine, fluoxetine, fluvoxamine, sertraline, methylsergide, trazodone, etc.);</LI>
<LI>Anti-psychotic drugs (haloperidol, chlorpromazine, levomepromazine, trifluoperazine, thioridazine, clozapine, risperidone, etc.);</LI>
<LI>Anti-viral (acyclovir);</LI>
<LI>Lithium;</LI>
<LI>Hydrocortisone;</LI>
<LI>Melatonin;</LI>
<LI>Benzodiazepines;</LI>
<LI>Levodopa-benserazide.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Comparison groups</HEADING>
<UL>
<LI>Placebo;</LI>
<LI>No intervention;</LI>
<LI>Other drug treatments.</LI>
</UL>
</SUBSECTION>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2016-04-06 10:10:57 +0100" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2013-08-07 12:59:54 +0100" MODIFIED_BY="Jenny Bellorini">
<UL>
<LI>Relief of KLS symptoms (hypersomnia, hyperphagia, abnormal behaviour) as measured by any objective or subjective validated scale.</LI>
</UL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2016-04-06 10:10:57 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Subjective sleep quality (any description of sleep quality; Epworth scale).</LI>
<LI>Sleep quality, as measured by night polysomnography (measured by sleep efficiency, total sleep time, arousal index).</LI>
<LI>Quality of life, as measured by a validated scale such as Short-Form Health Survey (SF-36), or a visual analogue scale.</LI>
<LI>Adverse events associated with treatments (to be described in terms of (i) numbers of participants withdrawing because of adverse events; and (ii) numbers of participants describing any side effect associated with the interventions).</LI>
</UL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2016-04-07 15:15:41 +0100" MODIFIED_BY="Márcio M. de Oliveira">
<P>The search strategies used for the original version of this review are recorded in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>. For the most recent update of this review, we searched the following databases:</P>
<UL>
<LI>The Cochrane Epilepsy Group Specialized Register (7 April 2016), using the search strategy set out in <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>;</LI>
<LI>The Cochrane Central Register of Controlled Trials (CENTRAL) via the Cochrane Register of Studies Online CRSO (7 April 2016), using the search strategy set out in <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>;</LI>
<LI>MEDLINE (Ovid, 1946 to 7 April 2016), using the search strategy outlined in <LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>;</LI>
<LI>LILACS (The Latin American and Caribbean Literature on Health Sciences Database; 7 April 2016), using the search strategy outlined in <LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK>;</LI>
<LI>
<A HREF="https://clinicaltrials.gov/">ClinicalTrials.gov</A> (7 April 2016), using the search term: "Kleine-Levin" OR "Kleine Levin";</LI>
<LI>
<A HREF="http://apps.who.int/trialsearch/">WHO International Clinical Trials Registry Platform ICTRP</A> (7 April 2016), using the search term: Kleine-Levin OR Kleine Levin in the Condition.</LI>
</UL>
<P>Previously, we searched SCOPUS as an alternative to EMBASE, using the search strategy outlined in <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK>, but this is no longer necessary, because randomised and quasi-randomised controlled trials in EMBASE are now included in CENTRAL.</P>
<P>We also searched the reference lists of sleep medicine textbooks, review articles, and the reference lists of articles identified by the search strategies described here.</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2016-04-06 10:11:56 +0100" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2016-04-06 10:11:26 +0100" MODIFIED_BY="[Empty name]">
<P>Two review authors (MMO and CC) undertook the review. We used the broad search strategy already described to obtain the titles and abstracts of studies pertaining to KLS of any cause. The same two review authors independently screened the titles and abstracts, and discarded studies that were not applicable; however, they initially retained studies and reviews that might have included relevant data or information on trials. The same two review authors independently assessed the retrieved abstracts, and if necessary, the full text of these studies to determine which studies satisfied the inclusion criteria.</P>
<P>We found no studies that met the eligibility criteria for inclusion. If studies that meet the inclusion criteria are identified for future updates of this review, we will apply the following methodology.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2016-04-06 10:11:56 +0100" MODIFIED_BY="[Empty name]">
<P>The same two review authors will independently carry out data extraction using standard data extraction forms, and then independently enter the data into the Review Manager software (<LINK REF="REF-RevMan-2012" TYPE="REFERENCE">RevMan 2012</LINK>). We will translate studies reported in non-English language journals before assessment. When more than one publication of a trial exists, we will group the articles, and for each available outcome, we will extract results from the publication with the most complete data. We will request any further information required from the original author by written correspondence, and will include any relevant information obtained in this manner in the review. We will resolve disagreements in consultation with a third review when necessary.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2016-04-06 10:11:56 +0100" MODIFIED_BY="[Empty name]">
<P>The two review authors will independently assess the risk of bias of the studies to be included, without blinding to authorship or journal, using the new Cochrane 'Risk of bias' tool (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). We will resolve discrepancies by discussion with GFP. 'Risk of bias' factors to be assessed include: randomisation, allocation concealment, blinding of investigators, participants and outcomes assessors, completeness of follow-up, selective reporting,</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2016-04-06 10:11:56 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Dichotomous outcomes</HEADING>
<P>For dichotomous outcomes (such as frequency of adverse reactions requiring withdrawal), we will express results as relative risk (RR) with 95% confidence interval (CI). We will pool data using the random-effects model but will also analyse the fixed-effect model to ensure the robustness of the model chosen and susceptibility to outliers.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Continuous outcomes</HEADING>
<P>When continuous scales of measurement are used to assess the effects of treatment (such as various of KLS symptoms or effects on quality of life), we will use the mean difference (MD), or the standardised mean difference (SMD) if different scales have been used.</P>
</SUBSECTION>
</EFFECT_MEASURES>
<MISSING_DATA MODIFIED="2016-04-06 10:11:56 +0100" MODIFIED_BY="[Empty name]">
<P>If possible, we will perform all analyses according to the intention-to-treat method, using the last reported observed response ('carry forward') and including all participants regardless of compliance or follow-up. </P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2016-04-06 10:11:56 +0100" MODIFIED_BY="[Empty name]">
<P>We will analyse heterogeneity using the Q statistic, a Chi² test on N-1 degrees of freedom, with an alpha of 0.10 used for statistical significance. We will also quantify inconsistency with the I² statistic, calculated by [(Q &#65293; df)/Q × 100%], which describes the percentage of variability in effect estimates caused by heterogeneity rather than by sampling error. A value greater than 50% will be considered to signify substantial heterogeneity (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
<P>When sufficient data are available, we will pool study findings according to subcategory to explore possible sources of heterogeneity. We will divide the studies according to the following:</P>
<UL>
<LI>Age of participants;</LI>
<LI>Severity of the disorder;</LI>
<LI>Type of medication given;</LI>
<LI>Methodological quality of the study (allocation concealment, blinding, intention-to-treat analysis).</LI>
</UL>
</HETEROGENEITY_ASSESSMENT>
<SENSITIVITY_ANALYSIS MODIFIED="2016-04-06 10:11:56 +0100" MODIFIED_BY="[Empty name]">
<P>We will perform 'a worst case scenario' analysis and will consider participants with missing data as treatment failures.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2016-04-07 13:06:49 +0100" MODIFIED_BY="Márcio M. de Oliveira">
<STUDY_DESCRIPTION MODIFIED="2016-04-07 13:06:49 +0100" MODIFIED_BY="Márcio M. de Oliveira">
<P>We initially identified 257 studies using the search strategy.</P>
<SUBSECTION>
<HEADING LEVEL="3">(1) Excluded studies</HEADING>
<P>The search identified 36 potentially eligible studies from the sources previously described. Of these, none were ultimately included in the review. All 36 studies were excluded because of study design: all were case reports or reviews. See the table of '<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>' for details.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">(2) Ongoing studies</HEADING>
<P>The review authors know of no ongoing studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">(3) Included studies</HEADING>
<P>No studies met the eligibility criteria for inclusion.</P>
</SUBSECTION>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2009-02-10 13:59:57 +0000" MODIFIED_BY="[Empty name]">
<P>No studies met the eligibility criteria for inclusion.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2016-04-06 10:12:03 +0100" MODIFIED_BY="[Empty name]">
<P>No studies met the eligibility criteria for inclusion.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2016-04-06 10:12:09 +0100" MODIFIED_BY="[Empty name]">
<P>We found no randomised, placebo-controlled trials of pharmacological treatments for KLS, and no studies could be included in this review. Kleine-Levin syndrome has a benign clinical course with spontaneous disappearance of symptoms; the findings of case reports excluded from this review were unpredictable. However, some case reports have described improvement in specific symptoms of KLS as follows:<BR/>
</P>
<UL>
<LI>Stimulant drugs, especially amphetamines, significantly improved sleepiness but did not improve other symptoms (<LINK REF="STD-Gallinek-1962" TYPE="STUDY">Gallinek 1962</LINK>).</LI>
<LI>Anti-depressant drugs had no effect on preventing relapse, except in one case, in which a monoamine oxidase inhibitor (moclobemide) was used (<LINK REF="STD-Chaudhry-1992" TYPE="STUDY">Chaudhry 1992</LINK>).</LI>
<LI>Anti-epileptic drugs showed, in a single case, improvement in abnormal behaviour when carbamazepine was used (<LINK REF="STD-Mukaddes-1999" TYPE="STUDY">Mukaddes 1999</LINK>).</LI>
<LI>Lithium significantly improved abnormal behaviour and recovery of symptoms (reducing the duration of episodes and decreasing relapses) (<LINK REF="STD-Kellet-1977" TYPE="STUDY">Kellet 1977</LINK>; <LINK REF="STD-Poppe-2003" TYPE="STUDY">Poppe 2003</LINK>; <LINK REF="STD-Smolik-1988" TYPE="STUDY">Smolik 1988</LINK>).</LI>
</UL>
<P>Unfortunately, no evidence was available to support the use of these therapies.</P>
<P>It is important to remember that the frequent occurrence of attacks and of severe behavioural disorders incapacitates patients with KLS both professionally and socially. We believe that double-blind, placebo-controlled therapeutical trials of drugs that can prevent or improve all symptoms of KLS are warranted, and that because of the rarity of the condition, these trials should have a multicentre design.</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2016-04-06 10:12:18 +0100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2016-04-06 10:12:18 +0100" MODIFIED_BY="[Empty name]">
<P>No evidence indicated that pharmacological treatment for Kleine-Levin syndrome was effective and safe.<BR/>
</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2016-04-06 10:12:18 +0100" MODIFIED_BY="[Empty name]">
<P>Therapeutic, double-blind, placebo-controlled drug trials for Kleine-Levin syndrome are needed that use a robust methodology, and in the light of the rarity of this condition, a multicentre design.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2013-08-07 13:05:16 +0100" MODIFIED_BY="[Empty name]">
<P>We would like to acknowledge Humberto Saconato who was on the review author team for the original protocol and review.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2013-08-07 13:05:43 +0100" MODIFIED_BY="[Empty name]">
<P>Marcio M de Oliveira: protocol development, literature searching, study selection, data extraction, statistical analysis, drafting of written submissions, development of final review.<BR/>Cristiane Conti: protocol development, literature searching, study selection, data extraction, statistical analysis, development of final review.<BR/>Gilmar F Prado: protocol development, literature searching, study selection, data extraction, statistical analysis, development of final review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2016-04-07 14:57:54 +0100" MODIFIED_BY="Márcio M. de Oliveira">
<STUDIES MODIFIED="2016-04-07 14:57:54 +0100" MODIFIED_BY="Márcio M. de Oliveira">
<INCLUDED_STUDIES/>
<EXCLUDED_STUDIES MODIFIED="2016-04-07 14:57:54 +0100" MODIFIED_BY="Márcio M. de Oliveira">
<STUDY DATA_SOURCE="PUB" ID="STD-Billiard-1998" MODIFIED="2009-02-10 14:13:17 +0000" MODIFIED_BY="[Empty name]" NAME="Billiard 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Billiard M, Carlander B</AU>
<TI>Wake disorders. I. Primary wake disorders</TI>
<SO>Revue Neurologique (Paris)</SO>
<YR>1998</YR>
<VL>154</VL>
<NO>2</NO>
<PG>111-29</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Billiard-2001" MODIFIED="2013-06-19 14:06:10 +0100" MODIFIED_BY="Dolores Matthews" NAME="Billiard 2001" YEAR="2001">
<REFERENCE MODIFIED="2013-06-19 14:06:10 +0100" MODIFIED_BY="Dolores Matthews" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Billiard M, Dauvilliers Y</AU>
<TI>Idiopathic hypersomnia</TI>
<SO>Sleep Medicine Reviews</SO>
<YR>2001</YR>
<VL>5</VL>
<NO>5</NO>
<PG>349-58</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brouns-SH-2012" MODIFIED="2016-04-07 13:27:15 +0100" MODIFIED_BY="Márcio M. de Oliveira" NAME="Brouns SH 2012" YEAR="2012">
<REFERENCE MODIFIED="2016-04-07 13:27:15 +0100" MODIFIED_BY="Márcio M. de Oliveira" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brouns SH, Schieveld J, Leue C.</AU>
<TI>The Kleine-Levin syndrome and the treatment with methylphenidate.</TI>
<SO>Tijdschr Psychiatr.</SO>
<YR>2012</YR>
<VL>54</VL>
<NO>8</NO>
<PG>747-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chaudhry-1992" MODIFIED="2009-02-10 14:14:15 +0000" MODIFIED_BY="[Empty name]" NAME="Chaudhry 1992" YEAR="1992">
<REFERENCE MODIFIED="2009-02-10 14:14:15 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chaudhry HR</AU>
<TI>Clinical use of moclobemide in Kleine-Levin syndrome</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1992</YR>
<VL>161</VL>
<PG>720</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chiles-1976" MODIFIED="2009-02-10 14:14:41 +0000" MODIFIED_BY="[Empty name]" NAME="Chiles 1976" YEAR="1976">
<REFERENCE MODIFIED="2009-02-10 14:14:41 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chiles JA, Wilkus RJ</AU>
<TI>Behavioural manifestations of Kleine-Levin syndrome</TI>
<SO>Diseases of the Nervous System</SO>
<YR>1976</YR>
<VL>37</VL>
<PG>646-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Crumley-1997" NAME="Crumley 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Crumley FE</AU>
<TI>Valproic acid for Kleine-Levin syndrome</TI>
<SO>Journal of the American Academy of Child and Adolescent Psychiatry</SO>
<YR>1997</YR>
<VL>36</VL>
<PG>868-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Crumley-1998" MODIFIED="2009-02-10 14:15:09 +0000" MODIFIED_BY="[Empty name]" NAME="Crumley 1998" YEAR="1998">
<REFERENCE MODIFIED="2009-02-10 14:15:09 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Crumley FE</AU>
<TI>Light therapy for Kleine-Levin syndrome</TI>
<SO>Journal of the American Academy of Child and Adolescent Psychiatry</SO>
<YR>1998</YR>
<VL>37</VL>
<NO>12</NO>
<PG>1245</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Duffy-1968" NAME="Duffy 1968" YEAR="1968">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Duffy JP, Davison K</AU>
<TI>A female case of the Kleine-Levin syndrome</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1968</YR>
<VL>114</VL>
<PG>77-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-El-Otmani-H-2013" MODIFIED="2016-04-07 13:22:51 +0100" MODIFIED_BY="Márcio M. de Oliveira" NAME="El Otmani H 2013" YEAR="2013">
<REFERENCE MODIFIED="2016-04-07 13:22:51 +0100" MODIFIED_BY="Márcio M. de Oliveira" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>El Otmani H, Lahlou I, Moutaouakil F, El Moutawakil B, Rafii MA, Slassi I</AU>
<TI>Invasive Kleine-Levin syndrome responding to valproate</TI>
<SO>Rev Neurol (Paris).</SO>
<YR>2013</YR>
<VL>169</VL>
<NO>1</NO>
<PG>94-5.</PG>
<IDENTIFIERS MODIFIED="2016-04-07 13:22:51 +0100" MODIFIED_BY="Márcio M. de Oliveira">
<IDENTIFIER MODIFIED="2016-04-07 13:21:06 +0100" MODIFIED_BY="Márcio M. de Oliveira" TYPE="DOI" VALUE="10.1016/j.neurol.2012.04.009"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gallinek-1962" NAME="Gallinek 1962" YEAR="1962">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gallinek A</AU>
<TI>The Kleine-Levin syndrome: hypersomnia, bulimia, and abnormal mental states</TI>
<SO>World Neurology</SO>
<YR>1962</YR>
<VL>3</VL>
<PG>235-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Goldberg-1983" NAME="Goldberg 1983" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Goldberg MA</AU>
<TI>The treatment of Kleine-Levin syndrome with lithium</TI>
<SO>Canadian Journal of Psychiatry</SO>
<YR>1983</YR>
<VL>28</VL>
<PG>491-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hart-1985" NAME="Hart 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hart EJ</AU>
<TI>Kleine-Levin syndrome: normal CSF monoamines and response to lithium therapy</TI>
<SO>Neurology</SO>
<YR>1985</YR>
<VL>35</VL>
<PG>1395-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kapson-B-2014" MODIFIED="2016-04-07 14:57:54 +0100" MODIFIED_BY="Márcio M. de Oliveira" NAME="Kapson B 2014" YEAR="2014">
<REFERENCE MODIFIED="2016-04-07 14:57:54 +0100" MODIFIED_BY="Márcio M. de Oliveira" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kapson B, Nayar S, Spiegel R.</AU>
<TI>Treatment of Kleine-Levin syndrome with acetazolamide.</TI>
<SO>J Clin Sleep Med.</SO>
<YR>2014</YR>
<VL>10</VL>
<NO>10</NO>
<PG>1153-4.</PG>
<IDENTIFIERS MODIFIED="2016-04-07 13:36:59 +0100" MODIFIED_BY="Márcio M. de Oliveira">
<IDENTIFIER MODIFIED="2016-04-07 13:36:59 +0100" MODIFIED_BY="Márcio M. de Oliveira" TYPE="DOI" VALUE="10.5664/jcsm.4124."/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kellet-1977" NAME="Kellet 1977" YEAR="1977">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kellet J</AU>
<TI>Lithium prophylaxis of periodic hypersomnia</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1977</YR>
<VL>130</VL>
<PG>312-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kornreich-2000" NAME="Kornreich 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kornreich C, Fossion P, Hoffmann G, Baleriaux M, Pelc I</AU>
<TI>Treatment of Kleine-Levin syndrome: melatonin on the starting block</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2000</YR>
<VL>61</VL>
<NO>3</NO>
<PG>215</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lenz-1980" MODIFIED="2009-02-10 14:16:01 +0000" MODIFIED_BY="[Empty name]" NAME="Lenz 1980" YEAR="1980">
<REFERENCE MODIFIED="2009-02-10 14:16:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lenz H</AU>
<TI>Kleine-Levin-syndrome</TI>
<SO>Wiener Medizinische Wochenschrift</SO>
<YR>1980</YR>
<VL>130</VL>
<NO>11</NO>
<PG>373-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mapari-2005" MODIFIED="2013-06-19 14:06:28 +0100" MODIFIED_BY="[Empty name]" NAME="Mapari 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-06-19 14:06:28 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mapari UU, Khealani BA, Ali S, Syed NA</AU>
<TI>Kleine-Levin syndrome</TI>
<SO>Journal of the College of Physicians and Surgeons &#65293; Pakistan</SO>
<YR>2005</YR>
<VL>15</VL>
<NO>1</NO>
<PG>46-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Masi-2000" NAME="Masi 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Masi G, Favilla L, Millepiedi S</AU>
<TI>The Kleine-Levin syndrome as a neuropsychiatric disorder: a case report</TI>
<SO>Psychiatry</SO>
<YR>2000</YR>
<VL>63</VL>
<NO>1</NO>
<PG>93-100</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Minvielle-2000" MODIFIED="2009-02-10 14:17:07 +0000" MODIFIED_BY="[Empty name]" NAME="Minvielle 2000" YEAR="2000">
<REFERENCE MODIFIED="2009-02-10 14:17:07 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Minvielle S</AU>
<TI>Klein-Levin syndrome: a neurological disease with psychiatric symptoms</TI>
<SO>Encephale</SO>
<YR>2000</YR>
<VL>26</VL>
<NO>4</NO>
<PG>71-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mukaddes-1999" NAME="Mukaddes 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mukaddes NM, Kora ME, Bilge S</AU>
<TI>Carbamazepine for Kleine-Levin syndrome</TI>
<SO>Journal of the American Academy of Child and Adolescent Psychiatry</SO>
<YR>1999</YR>
<VL>38</VL>
<PG>791-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Muratori-2002" MODIFIED="2013-06-19 14:06:45 +0100" MODIFIED_BY="Jenny Bellorini" NAME="Muratori 2002" YEAR="2002">
<REFERENCE MODIFIED="2013-06-19 14:06:45 +0100" MODIFIED_BY="Jenny Bellorini" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Muratori F, Bertini N, Masi G</AU>
<TI>Efficacy of lithium treatment in Kleine-Levin syndrome</TI>
<SO>European Psychiatry</SO>
<YR>2002</YR>
<VL>17</VL>
<PG>232-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pike-1994" MODIFIED="2009-02-10 14:17:38 +0000" MODIFIED_BY="[Empty name]" NAME="Pike 1994" YEAR="1994">
<REFERENCE MODIFIED="2009-02-10 14:17:38 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pike M, Stores G</AU>
<TI>Kleine-Levin syndrome: a cause of diagnostic confusion</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>1994</YR>
<VL>71</VL>
<PG>355-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Poppe-2003" MODIFIED="2013-06-19 14:06:59 +0100" MODIFIED_BY="[Empty name]" NAME="Poppe 2003" YEAR="Neuro">
<REFERENCE MODIFIED="2013-06-19 14:06:59 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Poppe M, Friebel D, Reuner U, Todt H, Koch R, Heubner G</AU>
<TI>The Kleine-Levin syndrome&#65293;effects of treatment with lithium</TI>
<SO>Neuropediatrics</SO>
<YR>2003</YR>
<VL>34</VL>
<PG>113-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Reimao-1998" MODIFIED="2009-02-10 14:18:34 +0000" MODIFIED_BY="[Empty name]" NAME="Reimao 1998" YEAR="1998">
<REFERENCE MODIFIED="2009-02-10 14:18:34 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Reimao R, Shimizu MH</AU>
<TI>Kleine-Levin syndrome: clinical course, polysomnography and multiple sleep latency test: case report</TI>
<SO>Arquivos de Neuro-psiquiatria</SO>
<YR>1998</YR>
<VL>56</VL>
<NO>3B</NO>
<PG>650-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rezvanian-E-2013" MODIFIED="2016-04-07 13:31:40 +0100" MODIFIED_BY="Márcio M. de Oliveira" NAME="Rezvanian E 2013" YEAR="2013">
<REFERENCE MODIFIED="2016-04-07 13:31:40 +0100" MODIFIED_BY="Márcio M. de Oliveira" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rezvanian E, Watson NF.</AU>
<TI>Kleine-levin syndrome treated with clarithromycin.</TI>
<SO>J Clin Sleep Med.</SO>
<YR>2013</YR>
<VL>9</VL>
<NO>11</NO>
<PG>1211-2.</PG>
<IDENTIFIERS MODIFIED="2016-04-07 13:31:40 +0100" MODIFIED_BY="Márcio M. de Oliveira">
<IDENTIFIER MODIFIED="2016-04-07 13:31:40 +0100" MODIFIED_BY="Márcio M. de Oliveira" TYPE="DOI" VALUE="10.5664/jcsm.3176"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Roth-1980" MODIFIED="2013-06-19 14:07:12 +0100" MODIFIED_BY="[Empty name]" NAME="Roth 1980" YEAR="1980">
<REFERENCE MODIFIED="2013-06-19 14:07:12 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Roth B, Smolik P, Soucek K</AU>
<TI>Kleine-Levin syndrome&#65293;lithium prophylaxis</TI>
<SO>Ceskoslovenská Psychiatrie</SO>
<YR>1980</YR>
<VL>76</VL>
<PG>156-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Savet-1986" MODIFIED="2009-02-10 14:19:32 +0000" MODIFIED_BY="[Empty name]" NAME="Savet 1986" YEAR="1986">
<REFERENCE MODIFIED="2009-02-10 14:19:32 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Savet JF, Robert H, Angeli C</AU>
<TI>A case of Kleine-Levin syndrome stabilized for over 1 year with carbamazepine</TI>
<SO>La Presse Médicale</SO>
<YR>1986</YR>
<VL>15</VL>
<PG>1281</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Smolik-1986" MODIFIED="2013-06-19 14:07:21 +0100" MODIFIED_BY="[Empty name]" NAME="Smolik 1986" YEAR="1986">
<REFERENCE MODIFIED="2013-06-19 14:07:21 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Smolik P, Roth B</AU>
<TI>Diagnosis, etiopathogenesis and treatment of Kleine-Levin syndrome</TI>
<SO>Ceskoslovenská Psychiatrie</SO>
<YR>1986</YR>
<VL>82</VL>
<NO>2</NO>
<PG>127-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Smolik-1988" MODIFIED="2013-06-19 14:10:33 +0100" MODIFIED_BY="[Empty name]" NAME="Smolik 1988" YEAR="1988">
<REFERENCE MODIFIED="2013-06-19 14:10:33 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Smolik P, Roth B</AU>
<TI>Kleine-Levin syndrome: etiopathogenesis and treatment</TI>
<SO>Acta Universitatis Carolinae. Medica Monographia</SO>
<YR>1988</YR>
<VL>128</VL>
<PG>5-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Suzuki-1998" MODIFIED="2009-02-10 14:22:04 +0000" MODIFIED_BY="[Empty name]" NAME="Suzuki 1998" YEAR="1998">
<REFERENCE MODIFIED="2009-02-10 14:22:04 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Suzuki H</AU>
<TI>Recurrent hypersomnia</TI>
<SO>Nippon Rinsho. Japanese Journal of Clinical Medicine</SO>
<YR>1998</YR>
<VL>56</VL>
<NO>2</NO>
<PG>365-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vlach-1962" MODIFIED="2009-02-10 14:22:30 +0000" MODIFIED_BY="[Empty name]" NAME="Vlach 1962" YEAR="1962">
<REFERENCE MODIFIED="2009-02-10 14:22:30 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vlach V</AU>
<TI>Periodical somnolence, bulimia and mental changes (Kleine-Levin syndrome)</TI>
<SO>Ceskoslovenská Psychiatrie</SO>
<YR>1962</YR>
<VL>25</VL>
<PG>401-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wenzel-1976" NAME="Wenzel 1976" YEAR="1976">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wenzel U</AU>
<TI>Kleine-Levin syndrome. Female cases and catamneses</TI>
<SO>Fortschritte der Neurologie, Psychiatrie, und ihrer Grenzgebiete</SO>
<YR>1976</YR>
<VL>44</VL>
<NO>4</NO>
<PG>137-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Will-1988" NAME="Will 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Will RG, Young JP, Thomas DJ</AU>
<TI>Kleine-Levin syndrome: report of two cases with onset of symptoms precipitated by head trauma</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1988</YR>
<VL>152</VL>
<PG>410-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wurthmann-1989" MODIFIED="2009-02-10 14:22:58 +0000" MODIFIED_BY="[Empty name]" NAME="Wurthmann 1989" YEAR="1989">
<REFERENCE MODIFIED="2009-02-10 14:22:58 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wurthmann C, Hartung HP, Dengler W, Gerhardt P</AU>
<TI>Kleine-Levin syndrome. The provocation of manic symptoms by an antidepressant and a therapeutic trial of carbamazepine</TI>
<SO>Deutsche Medizinische Wochenschrift</SO>
<YR>1989</YR>
<VL>114</VL>
<NO>40</NO>
<PG>1528-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yassa-1978" MODIFIED="2013-06-19 14:07:34 +0100" MODIFIED_BY="[Empty name]" NAME="Yassa 1978" YEAR="1978">
<REFERENCE MODIFIED="2013-06-19 14:07:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yassa R, Nair NP</AU>
<TI>The Kleine-Levin syndrome&#65293;a variant?</TI>
<SO>The Journal of Clinical Psychiatry</SO>
<YR>1978</YR>
<VL>39</VL>
<PG>254-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Y_x0131_lmaz-S-2015" MODIFIED="2016-04-07 14:50:07 +0100" MODIFIED_BY="Márcio M. de Oliveira" NAME="Y&#305;lmaz S 2015" YEAR="2015">
<REFERENCE MODIFIED="2016-04-07 14:50:07 +0100" MODIFIED_BY="Márcio M. de Oliveira" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Y&#305;lmaz S, Akça ÖF, Bilgiç A.</AU>
<TI>Treatment of Kleine-Levin Syndrome with Aripiprazole.</TI>
<SO>J Child Adolesc Psychopharmacol.</SO>
<YR>2015</YR>
<VL>25</VL>
<NO>5</NO>
<PG>450-1</PG>
<IDENTIFIERS MODIFIED="2016-04-07 13:47:33 +0100" MODIFIED_BY="Márcio M. de Oliveira">
<IDENTIFIER MODIFIED="2016-04-07 13:47:33 +0100" MODIFIED_BY="Márcio M. de Oliveira" TYPE="DOI" VALUE="10.1089/cap.2014.0169"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2016-04-07 13:23:14 +0100" MODIFIED_BY="Márcio M. de Oliveira">
<ADDITIONAL_REFERENCES MODIFIED="2016-04-07 13:23:14 +0100" MODIFIED_BY="Márcio M. de Oliveira">
<REFERENCE ID="REF-Chesson-1991" MODIFIED="2013-06-19 14:08:00 +0100" MODIFIED_BY="Dolores Matthews" NAME="Chesson 1991" TYPE="JOURNAL_ARTICLE">
<AU>Chesson A, Levine S, Kong LS, Lee S</AU>
<TI>Neuroendocrine evaluation in Kleine-Levin syndrome: Evidence of reduced dopaminergic tone during periods of hypersomnolence</TI>
<SO>Sleep</SO>
<YR>1991</YR>
<VL>14</VL>
<PG>226-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Critchley-1942" NAME="Critchley 1942" TYPE="JOURNAL_ARTICLE">
<AU>Critchley M, Hoffman HL</AU>
<TI>The syndrome of periodic somnolence and morbid hunger (Kleine-Levin)</TI>
<SO>British Medical Journal</SO>
<YR>1942</YR>
<VL>1</VL>
<PG>137-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Critchley-1962" MODIFIED="2010-08-04 13:32:47 +0100" MODIFIED_BY="[Empty name]" NAME="Critchley 1962" TYPE="JOURNAL_ARTICLE">
<AU>Critchley M</AU>
<TI>Periodic hypersomnia and megaphagia in adolescent males</TI>
<SO>Brain</SO>
<YR>1962</YR>
<VL>85</VL>
<PG>627-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dickersin-1994" MODIFIED="2009-02-10 14:24:20 +0000" MODIFIED_BY="[Empty name]" NAME="Dickersin 1994" TYPE="JOURNAL_ARTICLE">
<AU>Dickersin K, Scherer R, Lefebvre C</AU>
<TI>Identifying relevant studies for systematic reviews</TI>
<SO>BMJ</SO>
<YR>1994</YR>
<VL>309</VL>
<NO>6964</NO>
<PG>1286-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fenzi-1993" MODIFIED="2013-06-19 14:08:19 +0100" MODIFIED_BY="[Empty name]" NAME="Fenzi 1993" TYPE="JOURNAL_ARTICLE">
<AU>Fenzi F, Simonati A, Crosato F, Ghersini L, Rizzuto N</AU>
<TI>Clinical features of Kleine-Levin syndrome with localized encephalitis</TI>
<SO>Neuropediatrics</SO>
<YR>1993</YR>
<VL>24</VL>
<PG>292-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fulton-1929" NAME="Fulton 1929" TYPE="JOURNAL_ARTICLE">
<AU>Fulton JF, Bailey P</AU>
<TI>Tumors in the region of the third ventricle: their diagnosis and relation to pathological sleep</TI>
<SO>The Journal of Nervous and Mental Disease</SO>
<YR>1929</YR>
<VL>69</VL>
<PG>1-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Haugh-1983" MODIFIED="2009-02-10 14:24:57 +0000" MODIFIED_BY="[Empty name]" NAME="Haugh 1983" TYPE="JOURNAL_ARTICLE">
<AU>Haugh RM, Markesbery WR</AU>
<TI>Hypothalamic astrocytoma. Syndrome of hyperphagia, obesity, and disturbances of behaviour and endocrine and autonomic function</TI>
<SO>Archives of Neurology</SO>
<YR>1983</YR>
<VL>40</VL>
<PG>560-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2016-04-06 10:13:18 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<YR>2011</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ICSD-1990" MODIFIED="2013-08-07 11:18:27 +0100" MODIFIED_BY="Dolores Matthews" NAME="ICSD 1990" TYPE="BOOK_SECTION">
<AU>Thorpy MJ, Chairman</AU>
<TI>International Classification of Sleep Disorders: Diagnostic and Coding Manual</TI>
<SO>Diagnostic Classification Steering Committee</SO>
<YR>1990</YR>
<PB>American Sleep Disorders Association</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ISCD_x002d_3-2014" MODIFIED="2016-04-07 13:23:14 +0100" MODIFIED_BY="Márcio M. de Oliveira" NAME="ISCD-3 2014" TYPE="JOURNAL_ARTICLE">
<AU>Darien, IL: American Academy of Sleep Medicine</AU>
<TI>American Academy of Sleep Medicine.</TI>
<SO>International Classification of Sleep Disorders.3rd ed</SO>
<YR>2014</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kleine-1925" NAME="Kleine 1925" TYPE="JOURNAL_ARTICLE">
<AU>Kleine W</AU>
<TI>Periodische Schlafsucht</TI>
<SO>Monatsschrift für Psychiatrie und Neurologie</SO>
<YR>1925</YR>
<VL>57</VL>
<PG>285</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Koerber-1984" MODIFIED="2009-02-10 14:25:28 +0000" MODIFIED_BY="[Empty name]" NAME="Koerber 1984" TYPE="JOURNAL_ARTICLE">
<AU>Koerber RK, Torkelson R, Haven G, Donaldson J, Cohen SM, Case M</AU>
<TI>Increased cerebrospinal fluid 5-hydroxytryptamine and 5-hydroxyindoleacetic acid in Kleine-Levin syndrome</TI>
<SO>Neurology</SO>
<YR>1984</YR>
<VL>34</VL>
<PG>1597-600</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lefebvre-1996" NAME="Lefebvre 1996" TYPE="CONFERENCE_PROC">
<AU>Lefebvre C, McDonald S</AU>
<TI>Development of a sensitive search strategy for reports of randomized controlled trials in EMBASE</TI>
<SO>Fourth International Cochrane Colloquium</SO>
<YR>1996 Oct 20-24; Adelaide (Australia)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lefebvre-2011" MODIFIED="2016-04-06 10:13:40 +0100" MODIFIED_BY="[Empty name]" NAME="Lefebvre 2011" TYPE="OTHER">
<AU>Lefebvre C, Manheimer E, Glanville J </AU>
<TI>Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). <I>Cochrane Handbook for Systematic Reviews of Interventions</I> Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from: http://handbook.cochrane.org/</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Levin-1936" NAME="Levin 1936" TYPE="JOURNAL_ARTICLE">
<AU>Levin M</AU>
<TI>Periodic somnolence and morbid hunger: a new syndrome</TI>
<SO>Brain</SO>
<YR>1936</YR>
<VL>59</VL>
<PG>494-504</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Merriam-1986" MODIFIED="2009-02-10 14:25:48 +0000" MODIFIED_BY="[Empty name]" NAME="Merriam 1986" TYPE="JOURNAL_ARTICLE">
<AU>Merriam AE</AU>
<TI>Kleine-Levin syndrome following acute viral encephalitis</TI>
<SO>Biological Psychiatry</SO>
<YR>1986</YR>
<VL>21</VL>
<PG>1301-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2012" MODIFIED="2013-08-07 13:06:59 +0100" MODIFIED_BY="[Empty name]" NAME="RevMan 2012" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2012</YR>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Version 5.2. Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Russel-1992" MODIFIED="2013-06-19 14:09:20 +0100" MODIFIED_BY="Dolores Matthews" NAME="Russel 1992" TYPE="JOURNAL_ARTICLE">
<AU>Russel J, Grunstein R</AU>
<TI>Kleine-Levin syndrome: a case report</TI>
<SO>The Australian and New Zealand Journal of Psychiatry</SO>
<YR>1992</YR>
<VL>26</VL>
<NO>1</NO>
<PG>119-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Salter-1993" MODIFIED="2009-02-10 14:26:19 +0000" MODIFIED_BY="[Empty name]" NAME="Salter 1993" TYPE="JOURNAL_ARTICLE">
<AU>Salter MS, White PD</AU>
<TI>A variant of Kleine-Levin syndrome precipitated by both Epstein-Barr and varicella-zoster virus infections</TI>
<SO>Biological Psychiatry</SO>
<YR>1993</YR>
<VL>33</VL>
<PG>388-90</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2016-03-23 14:09:03 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Oliveira-2007" MODIFIED="2016-03-23 14:09:03 +0000" MODIFIED_BY="[Empty name]" NAME="Oliveira 2007" TYPE="COCHRANE_PROTOCOL">
<AU>Oliveira MM, Conti C, Saconato H, Fernandes do Prado G</AU>
<TI>Pharmacological treatment for Kleine-Levin Syndrome</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2016-03-23 14:09:03 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2016-03-23 14:09:03 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006685"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Oliveira-2009" MODIFIED="2013-08-07 13:23:41 +0100" MODIFIED_BY="[Empty name]" NAME="Oliveira 2009" TYPE="COCHRANE_REVIEW">
<AU>Oliveira MM, Conti C, Saconato H, Prado GF</AU>
<TI>Pharmacological treatment for Kleine-Levin Syndrome</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2013-08-07 13:23:41 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-08-07 13:23:41 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006685.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Oliveira-2013" MODIFIED="2016-03-23 14:07:20 +0000" MODIFIED_BY="[Empty name]" NAME="Oliveira 2013" TYPE="COCHRANE_REVIEW">
<AU>Oliveira MM, Conti C, Prado GF</AU>
<TI>Pharmacological treatment for Kleine-Levin syndrome</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2013</YR>
<NO>8</NO>
<IDENTIFIERS MODIFIED="2016-03-23 14:07:20 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2016-03-23 14:07:20 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006685.pub3"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2016-04-07 13:49:53 +0100" MODIFIED_BY="Márcio M. de Oliveira">
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2016-04-07 13:49:53 +0100" MODIFIED_BY="Márcio M. de Oliveira" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2013-06-19 14:05:52 +0100" MODIFIED_BY="Dolores Matthews" STUDY_ID="STD-Billiard-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-19 14:05:52 +0100" MODIFIED_BY="Dolores Matthews">
<P>Review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-19 14:05:52 +0100" MODIFIED_BY="Dolores Matthews" STUDY_ID="STD-Billiard-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-19 14:05:52 +0100" MODIFIED_BY="Dolores Matthews">
<P>Review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-04-07 13:49:53 +0100" MODIFIED_BY="Márcio M. de Oliveira" STUDY_ID="STD-Brouns-SH-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-04-07 13:49:53 +0100" MODIFIED_BY="Márcio M. de Oliveira">
<P>Case report</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-19 14:05:52 +0100" MODIFIED_BY="Dolores Matthews" STUDY_ID="STD-Chaudhry-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-19 14:05:52 +0100" MODIFIED_BY="Dolores Matthews">
<P>Case report.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-19 14:05:52 +0100" MODIFIED_BY="Dolores Matthews" STUDY_ID="STD-Chiles-1976">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-19 14:05:52 +0100" MODIFIED_BY="Dolores Matthews">
<P>Case report.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-19 14:05:52 +0100" MODIFIED_BY="Dolores Matthews" STUDY_ID="STD-Crumley-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-19 14:05:52 +0100" MODIFIED_BY="Dolores Matthews">
<P>Case report.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-19 14:05:53 +0100" MODIFIED_BY="Dolores Matthews" STUDY_ID="STD-Crumley-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-19 14:05:53 +0100" MODIFIED_BY="Dolores Matthews">
<P>Case report.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-19 14:05:53 +0100" MODIFIED_BY="Dolores Matthews" STUDY_ID="STD-Duffy-1968">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-19 14:05:53 +0100" MODIFIED_BY="Dolores Matthews">
<P>Case report.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-04-07 13:12:03 +0100" MODIFIED_BY="Márcio M. de Oliveira" STUDY_ID="STD-El-Otmani-H-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-04-07 13:12:03 +0100" MODIFIED_BY="Márcio M. de Oliveira">
<P>Case Report</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-19 14:05:53 +0100" MODIFIED_BY="Dolores Matthews" STUDY_ID="STD-Gallinek-1962">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-19 14:05:53 +0100" MODIFIED_BY="Dolores Matthews">
<P>Case report.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-19 14:05:54 +0100" MODIFIED_BY="Dolores Matthews" STUDY_ID="STD-Goldberg-1983">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-19 14:05:54 +0100" MODIFIED_BY="Dolores Matthews">
<P>Case report.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-19 14:05:54 +0100" MODIFIED_BY="Dolores Matthews" STUDY_ID="STD-Hart-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-19 14:05:54 +0100" MODIFIED_BY="Dolores Matthews">
<P>Case report.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-04-07 13:49:00 +0100" MODIFIED_BY="Márcio M. de Oliveira" STUDY_ID="STD-Kapson-B-2014">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-04-07 13:49:00 +0100" MODIFIED_BY="Márcio M. de Oliveira">
<P>Case Report</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-19 14:05:54 +0100" MODIFIED_BY="Dolores Matthews" STUDY_ID="STD-Kellet-1977">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-19 14:05:54 +0100" MODIFIED_BY="Dolores Matthews">
<P>Case report.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-19 14:05:54 +0100" MODIFIED_BY="Dolores Matthews" STUDY_ID="STD-Kornreich-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-19 14:05:54 +0100" MODIFIED_BY="Dolores Matthews">
<P>Case report.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-19 14:05:55 +0100" MODIFIED_BY="Dolores Matthews" STUDY_ID="STD-Lenz-1980">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-19 14:05:55 +0100" MODIFIED_BY="Dolores Matthews">
<P>Case report.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-19 14:05:55 +0100" MODIFIED_BY="Dolores Matthews" STUDY_ID="STD-Mapari-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-19 14:05:55 +0100" MODIFIED_BY="Dolores Matthews">
<P>Case report.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-19 14:05:55 +0100" MODIFIED_BY="Dolores Matthews" STUDY_ID="STD-Masi-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-19 14:05:55 +0100" MODIFIED_BY="Dolores Matthews">
<P>Case report.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-19 14:05:56 +0100" MODIFIED_BY="Dolores Matthews" STUDY_ID="STD-Minvielle-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-19 14:05:56 +0100" MODIFIED_BY="Dolores Matthews">
<P>Case report.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-19 14:05:56 +0100" MODIFIED_BY="Dolores Matthews" STUDY_ID="STD-Mukaddes-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-19 14:05:56 +0100" MODIFIED_BY="Dolores Matthews">
<P>Case report.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-19 14:05:57 +0100" MODIFIED_BY="Dolores Matthews" STUDY_ID="STD-Muratori-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-19 14:05:57 +0100" MODIFIED_BY="Dolores Matthews">
<P>Case report.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-19 14:05:57 +0100" MODIFIED_BY="Dolores Matthews" STUDY_ID="STD-Pike-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-19 14:05:57 +0100" MODIFIED_BY="Dolores Matthews">
<P>Case report.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-19 14:05:57 +0100" MODIFIED_BY="Dolores Matthews" STUDY_ID="STD-Poppe-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-19 14:05:57 +0100" MODIFIED_BY="Dolores Matthews">
<P>Case report and review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-19 14:05:57 +0100" MODIFIED_BY="Dolores Matthews" STUDY_ID="STD-Reimao-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-19 14:05:57 +0100" MODIFIED_BY="Dolores Matthews">
<P>Case report.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-04-07 13:49:15 +0100" MODIFIED_BY="Márcio M. de Oliveira" STUDY_ID="STD-Rezvanian-E-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-04-07 13:49:15 +0100" MODIFIED_BY="Márcio M. de Oliveira">
<P>Case Report</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-19 14:05:57 +0100" MODIFIED_BY="Dolores Matthews" STUDY_ID="STD-Roth-1980">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-19 14:05:57 +0100" MODIFIED_BY="Dolores Matthews">
<P>Case report.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-19 14:05:58 +0100" MODIFIED_BY="Dolores Matthews" STUDY_ID="STD-Savet-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-19 14:05:58 +0100" MODIFIED_BY="Dolores Matthews">
<P>Case report.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-19 14:05:58 +0100" MODIFIED_BY="Dolores Matthews" STUDY_ID="STD-Smolik-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-19 14:05:58 +0100" MODIFIED_BY="Dolores Matthews">
<P>Case report and review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-19 14:05:58 +0100" MODIFIED_BY="Dolores Matthews" STUDY_ID="STD-Smolik-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-19 14:05:58 +0100" MODIFIED_BY="Dolores Matthews">
<P>Case report.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-19 14:05:58 +0100" MODIFIED_BY="Dolores Matthews" STUDY_ID="STD-Suzuki-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-19 14:05:58 +0100" MODIFIED_BY="Dolores Matthews">
<P>Review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-19 14:05:59 +0100" MODIFIED_BY="Dolores Matthews" STUDY_ID="STD-Vlach-1962">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-19 14:05:59 +0100" MODIFIED_BY="Dolores Matthews">
<P>Case report.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-19 14:05:59 +0100" MODIFIED_BY="Dolores Matthews" STUDY_ID="STD-Wenzel-1976">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-19 14:05:59 +0100" MODIFIED_BY="Dolores Matthews">
<P>Case report.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-19 14:05:59 +0100" MODIFIED_BY="Dolores Matthews" STUDY_ID="STD-Will-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-19 14:05:59 +0100" MODIFIED_BY="Dolores Matthews">
<P>Case report.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-19 14:05:59 +0100" MODIFIED_BY="Dolores Matthews" STUDY_ID="STD-Wurthmann-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-19 14:05:59 +0100" MODIFIED_BY="Dolores Matthews">
<P>Case report.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-19 14:06:00 +0100" MODIFIED_BY="Dolores Matthews" STUDY_ID="STD-Yassa-1978">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-19 14:06:00 +0100" MODIFIED_BY="Dolores Matthews">
<P>Case report.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-04-07 13:49:33 +0100" MODIFIED_BY="Márcio M. de Oliveira" STUDY_ID="STD-Y_x0131_lmaz-S-2015">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-04-07 13:49:33 +0100" MODIFIED_BY="Márcio M. de Oliveira">
<P>Case report</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES"/>
<FIGURES/>
<FEEDBACK/>
<APPENDICES MODIFIED="2016-04-03 22:46:32 +0100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2011-10-26 12:55:40 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2010-03-17 11:49:20 +0000" MODIFIED_BY="[Empty name]">Search strategies for original version of this review</TITLE>
<APPENDIX_BODY MODIFIED="2011-10-26 12:55:40 +0100" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Epilepsy Group Specialized Register (1 December 2007) and the Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library</I> Issue 3, 2007) using the following terms</P>
<P>:#1 KLEINE-LEVIN SYNDROME<BR/>#2 (Kleine-Levin* next syndrome*)<BR/>#3 (periodic next hypersomnia next sleep*)<BR/>#4 (compulsive next eating*)<BR/>#5 (hyperphagia or megaphagia or polyphagia*)<BR/>#6 (hypersexuality)<BR/>#7 (KLS)<BR/>#8 (#1 or #2 or #3 or #4 or #5 or #6 or #7)</P>
<P>We also searched the following electronic databases.</P>
<P>- MEDLINE (1966 to December 2007) using the optimally sensitive strategy developed for the Cochrane Collaboration for the identification of randomized controlled trials (<LINK REF="REF-Dickersin-1994" TYPE="REFERENCE">Dickersin 1994</LINK>).</P>
<P>- EMBASE (1980 to December 2007) using a search strategy adapted from that developed for the Cochrane Collaboration for the identification of randomized controlled clinical trials (<LINK REF="REF-Lefebvre-1996" TYPE="REFERENCE">Lefebvre 1996</LINK>).</P>
<P>- LILACS (1982 to December 2007) using a search strategy adapted for the identification of randomized controlled clinical trials.</P>
<SUBSECTION>
<HEADING LEVEL="3">MEDLINE search strategy (1966 to December 2007)</HEADING>
<P>((kleine[All Fields] AND levin[All Fields]) OR ("kleine-levin syndrome"[MeSH Terms] OR kleine levin syndrome[Text Word])) AND (megaphagia[All Fields] OR (("disorders of excessive somnolence"[TIAB] NOT Medline[SB]) OR "disorders of excessive somnolence"[MeSH Terms] OR hypersomnia[Text Word]) OR hypersexuality[All Fields] OR ("hyperphagia"[MeSH Terms] OR hyperphagia[Text Word]))</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">EMBASE search strategy (1980 to December 2007)</HEADING>
<P>'kleine levin' AND ('syndrome'/exp OR 'syndrome') AND 'kleine levin' AND ('hyperphagia'/exp OR 'hyperphagia') AND megaphagia AND ('polyphagia'/exp OR 'polyphagia') AND ('hypersomnia'/exp OR 'hypersomnia') AND periodic AND ('hypersomnia'/exp OR 'hypersomnia') AND ('hypersexuality'/exp OR 'hypersexuality') AND kls</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">LILACS search strategy (1982 to December 2007)</HEADING>
<P>"sindrome de KLEINE-levin" or (tw kleine and tw levin) [Descritor de assunto]</P>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2016-04-03 22:46:32 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2013-05-02 20:40:23 +0100" MODIFIED_BY="[Empty name]">Cochrane Epilepsy Group Specialized Register search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2016-03-15 17:30:31 +0000" MODIFIED_BY="Márcio M. de Oliveira">
<P>#1 MeSH DESCRIPTOR Kleine-Levin Syndrome Explode All</P>
<P>#2 Kleine-Levin* next syndrome*</P>
<P>#3 periodic next hypersomnia next sleep*</P>
<P>#4 compulsive next eating*</P>
<P>#5 hyperphagia or megaphagia or polyphagia*</P>
<P>#6 hypersexuality</P>
<P>#7 KLS</P>
<P>#8 (#1 or #2 or #3 or #4 or #5 or #6 or #7) AND INREGISTER AND &gt;02/05/2013:CRSCREATED</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2016-03-15 17:30:37 +0000" MODIFIED_BY="Márcio M. de Oliveira" NO="3">
<TITLE MODIFIED="2016-03-15 17:30:34 +0000" MODIFIED_BY="Márcio M. de Oliveira">CENTRAL via CRSO search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2016-03-15 17:30:37 +0000" MODIFIED_BY="Márcio M. de Oliveira">
<P>#1 MESH DESCRIPTOR Kleine-Levin Syndrome EXPLODE ALL TREES</P>
<P>#2 (Kleine AND Levin):TI,AB,KY</P>
<P>#3 #1 OR #2</P>
<P>#4 31/05/2013 TO 31/07/2015:DL</P>
<P>#5 #3 AND #4</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2016-03-15 17:30:38 +0000" MODIFIED_BY="Márcio M. de Oliveira" NO="4">
<TITLE MODIFIED="2010-03-17 11:56:17 +0000" MODIFIED_BY="[Empty name]">MEDLINE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2016-03-15 17:30:38 +0000" MODIFIED_BY="Márcio M. de Oliveira">
<P>This strategy is based on the Cochrane Highly Sensitive Search Strategy for identifying randomized trials published in <LINK REF="REF-Lefebvre-2011" TYPE="REFERENCE">Lefebvre 2011</LINK>.</P>
<P>1. exp Kleine-Levin Syndrome/</P>
<P>2. (Kleine and Levin).tw.</P>
<P>3. 1 or 2</P>
<P>4. (randomized controlled trial or controlled clinical trial).pt. or (randomi?ed or placebo or randomly).ab.</P>
<P>5. clinical trials as topic.sh.</P>
<P>6. trial.ti.</P>
<P>7. 4 or 5 or 6</P>
<P>8. exp animals/ not humans.sh.</P>
<P>9. 7 not 8</P>
<P>10. 3 and 9</P>
<P>11. limit 10 to ed=20130502-20150707</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-05" MODIFIED="2016-03-31 22:56:10 +0100" MODIFIED_BY="[Empty name]" NO="5">
<TITLE MODIFIED="2010-03-17 11:56:26 +0000" MODIFIED_BY="[Empty name]">LILACS search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2016-03-15 17:30:31 +0000" MODIFIED_BY="Márcio M. de Oliveira">
<P>(tw:("kleine levin")) OR (mh:("kleine-levin syndrome")) AND (instance:"regional") AND ( type_of_study:("case_control" OR "cohort"))</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-06" MODIFIED="2016-03-31 22:56:10 +0100" MODIFIED_BY="[Empty name]" NO="6">
<TITLE MODIFIED="2013-05-02 20:40:34 +0100" MODIFIED_BY="[Empty name]">SCOPUS search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2013-05-02 20:35:26 +0100" MODIFIED_BY="[Empty name]">
<P>(TITLE("Kleine-Levin") OR ABS("Kleine-Levin")) AND (TITLE((randomiz* OR randomis* OR controlled OR placebo OR blind* OR unblind* OR "parallel group" OR crossover OR "cross over" OR cluster OR "head to head") PRE/2 (trial OR method OR procedure OR study)) OR ABS((randomiz* OR randomis* OR controlled OR placebo OR blind* OR unblind* OR "parallel group" OR crossover OR "cross over" OR cluster OR "head to head") PRE/2 (trial OR method OR procedure OR study)))</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>